Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Ast...(irector Dallas Breast Center Dallas TX a...),Health

Date:9/22/2008

irector, Dallas Breast Center, Dallas, TX and David Wazer, MD, professor and chairman, Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA and the Department of Radiation Oncology, Warren Alpert Medical School of Brown University, Providence, RI.

The company also recently announced the launch of the Axxent Xpress(TM) Mobile Electronic Brachytherapy Vehicles, which can be configured with up to three Axxent HDR Controllers. In order to expand and improve access to critical radiation therapy, Xoft collaborated with Medical Coaches, a leading manufacturer of custom mobile medical and specialty vehicles, to design and manufacture the specialized medical vehicles, as well as complete the extensive Department of Transportation (DOT) certification process.

As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in many clinical settings under the supervision of a radiation oncologist, without the need for a shielded room. As a result, tens of thousands of patients annually will have greater access to therapy that is delivered more easily and conveniently.

About Xoft Inc.

Xoft, founded in 1998, develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. Xoft provides a "point of care model" that is patient centric and accessible to a broader spectrum of patients and their physicians. The Axxent treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healt
'/>"/>

SOURCE Xoft Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
2. ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting
3. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
4. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
5. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
6. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
9. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting